News Story Headlines
November 30, 2022
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
November 5, 2022
- Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy...
November 18, 2022
Webinar: Updates in ATTR Cardiac and Neurological Amyloidosis: What’s new and exciting for 2022 and beyond
October 2022 Webinar Event
This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic strategies, and the...
November 16, 2022
2022 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter here!
November 16, 2022
2022 Fall Newsletter
Be sure to catch up on the latest happenings in our fall newsletter here!
November 1, 2022
Webinar: Updates in ATTR Cardiac and Neurological Amyloidosis: What’s new and exciting for 2022 and beyond
October 2022 Webinar Event
This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic strategies, and the evolving...